ReviewBiosensors2021
Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma.
Review in Biosensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 95 citations in OpenAlex.
- Construction and application of high-quality development model for public hospitals oriented to regional medical center: an integrated advanced imaging platform for computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography services.Journal of applied clinical medical physics · 2026Article
- LncSNHGs: new targets in osteosarcoma.Cancer gene therapy · 2025Review
- Antitumor Effects of Hesperidin and Cisplatin on Human Osteosarcoma Cells Through Inhibiting Proliferation and Inducing Mitochondrial-Mediated Apoptosis.Medicina (Kaunas, Lithuania) · 2025Article
- Unveiling FDA-approved Drugs and Formulations in the Management of Bladder Cancer: A Review.Current pharmaceutical biotechnology · 2025Review
- Advancements in nanotechnology for diagnostics: a literature review, part II: advanced techniques in nuclear and optical imaging.Nanomedicine (London, England) · 2025Review
- Stimuli-responsive Nano/Biomaterials for Smart Drug Delivery in Cardiovascular Diseases: Promises, Challenges and Outlooks.Current medicinal chemistry · 2025Review
- Smart molecular probes with controllable photophysical property for smart medicine.Smart molecules : open access · 2024Review
- Green synthesis of Zn-doped TIOBMC plant biology · 2024Article
- Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress.Pharmaceutics · 2024Review
- Advanced nanoparticles in osteoarthritis treatment.Biomaterials translational · 2024Review
- A risk score model based on endoplasmic reticulum stress related genes for predicting prognostic value of osteosarcoma.BMC musculoskeletal disorders · 2023Article
- The Use of Hydrogels for the Treatment of Bone Osteosarcoma via Localized Drug-Delivery and Tissue Regeneration: A Narrative Review.Gels (Basel, Switzerland) · 2023Review
- Contribution of Mitochondrial Activity to Doxorubicin-Resistance in Osteosarcoma Cells.Cancers · 2023Article
- PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway.Cancer medicine · 2023Article
- A mini-review on the emerging role of nanotechnology in revolutionizing orthopedic surgery: challenges and the road ahead.Frontiers in bioengineering and biotechnology · 2023Review
- Polymer-based nanosystems and their applications in bone anticancer therapy.Frontiers in chemistry · 2023Review
- Brief review: Applications of nanocomposite in electrochemical sensor and drugs delivery.Frontiers in chemistry · 2023Review
- Ensemble Technique Coupled with Deep Transfer Learning Framework for Automatic Detection of Tuberculosis from Chest X-ray Radiographs.Healthcare (Basel, Switzerland) · 2022Article
- Review
- Nanotechnology for research and treatment of the intestine.Journal of nanobiotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones.OSA is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome disorganization, chromosomal modifications, deregulation of tumor suppressor genes, and DNA repair defects are the factors most responsible for OSA development. Despite significant advances in the diagnosing and treatment of OSA, patients' overall survival has not improved within the last twenty years. Lately, advances in modern nanotechnology have spurred development in OSA management and offered several advantages to overcome the drawbacks of conventional therapies. This technology has allowed the practical design of nanoscale devices combined with numerous functional molecules, including tumor-specific ligands, antibodies, anti-cancer drugs, and imaging probes. Thanks to their small sizes, desirable drug encapsulation efficiency, and good bioavailability, functionalized nanomaterials have found wide-spread applications for combating OSA progression. This review invokes the possible utility of engineered nanomaterials in OSA diagnosis and treatment, motivating the researchers to seek new strategies for tackling the challenges associated with it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.